OncoMatch

OncoMatch/Clinical Trials/NCT07230405

A Phase II Study of SKB571 in Patients With Lung Cancer

Is NCT07230405 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies SKB571 for for lung cancer (non-small cell).

Phase 2RecruitingSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.NCT07230405Data as of Jun 2026Location: China

Treatment: SKB571 forThis is a multicenter, phase II study. The purpose of this study is to evaluate the safety and preliminary anti-tumor activity of SKB571 in patients with advanced non-small cell lung cancer. Eligible subjects will receive SKB571 monotherapy, until radiographic disease progression, intolerable toxicity, discontinuation of study treatment required by the subject, or other protocol-specified treatment discontinuation criteria, whichever occurs first.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

SKB571 for

Cancer type

Non-Small Cell Lung Carcinoma

Disease stage

Metastatic disease required

locally advanced or metastatic NSCLC

Performance status

ECOG 0–1(Restricted strenuous activity)

Demographics

Ages ≤ 75

Prior therapy

Cannot have received: chemotherapy

Subjects who have received chemotherapy...within 4 weeks prior to the first dose of study treatment

Cannot have received: immunotherapy

Subjects who have received...immunotherapy...within 4 weeks prior to the first dose of study treatment

Cannot have received: biological therapy

Subjects who have received...biological therapy within 4 weeks prior to the first dose of study treatment

Lab requirements

Blood counts

Kidney function

Liver function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT07230405 currently recruiting?

Yes, this trial is currently recruiting patients.

Are there prior therapy exclusions?

Yes. Prior chemotherapy, immunotherapy, biological therapy disqualifies patients from enrollment.

Is there an age limit?

Yes. Patients must be 75 years or younger.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify